Basso Capital Management’s AbbVie ABBV Stock Holding History

Basso Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-472	Closed	-$103K	–	139
2026 Q1	$103K	Hold	472	–	–	0.06%	78
2025 Q4	$108K	Buy	+472	New	+$108K	0.06%	70
2023 Q2	–	Sell	-6,100	Closed	-$972K	–	90
2023 Q1	$972K	Hold	6,100	–	–	0.94%	29
2022 Q4	$986K	Buy	+6,100	New	+$935K	1.06%	28

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Basso Capital Management's ABBV Position: Q2 2026 in Review

Basso Capital Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 472 shares — an estimated $103K sold.

Basso Capital Management first reported a position in ABBV in Q4 2022 and held it in 4 quarters. The position peaked at $986K in Q4 2022. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Basso Capital Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Basso Capital Management sold 472 AbbVie shares in Q2 2026, an estimated $103K.
Basso Capital Management first reported a position in AbbVie in Q4 2022 and held it in 4 quarters.
Basso Capital Management's AbbVie position peaked at $986K in Q4 2022.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Basso Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.